| This week's sponsor is FierceBiotech. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Thursday, January 3, 2019 The long-predicted deal-making boom in Big Pharma started with a bang on Wednesday, as Bristol-Myers Squibb announced it will buy Celgene in a cash and stock transaction worth $74 billion. The deal values Celgene at $102.43 a share—54% higher than its closing price on Wednesday evening. |
|
|
Top Stories Of The Week Wednesday, January 2, 2019 If in 2017, the FDA was trying to make up for lost time, the agency went into overdrive in 2018, approving more than 50 new molecular entities. Wednesday, January 2, 2019 We saw a major milestone in FDA approvals in 2018, but a political deadlock that led to a partial government shutdown before Christmas could take some of the shine off a golden year. Friday, December 28, 2018 The most expensive drugs in the U.S. feature commercial hits as well as lesser-known ones, with several Big Pharma products making an appearance. Why are the usual suspects missing? We're leaving out the drugs you can't get at a pharmacy. Thursday, January 3, 2019 Ex-Novartis Oncology CEO Liz Barrett has joined UroGen Pharma. Barrett is taking over as CEO of the uro-oncology specialist at a time when it is working on a rolling NDA that could lead to its first drug approval. Wednesday, January 2, 2019 Pfizer, Eli Lilly, Sanofi and Johnson & Johnson chimed in among the 146 official comments on the federal government’s plan to tag pharma TV ads with drug prices. Thursday, December 27, 2018 In January, Boston Scientific handed over $90 million for a portion of Millipede's shares. Now, the devicemaker is paying $325 million to pick up the rest of Millipede’s shares. Thursday, December 20, 2018 Industry wisdom is that there's nothing new to learn about tablet-making, but that idiom was turned on its head this year when the FDA learned a manufacturing process for “sartan” drugs could turn them into cancer-causing time bombs. Wednesday, January 2, 2019 Sanofi and Merck scored an FDA approval for their Vaxelis vaccine to ring in the new year, but they’re not planning to launch until 2020. The partners plan to spend 2019 building up supplies of the six-in-one pediatric shot, the first hexavalent childhood vaccine ever. Wednesday, January 2, 2019 Hong Kong-based MabSpace, a biotech company, has merged with bioprocessing specialist HJB to form a new biotherapeutics organization dubbed Transcenta Holding. Thursday, January 3, 2019 Researchers at the University of Toronto and the University of California, San Francisco, have discovered that some white blood cells produced in the gut can dampen brain inflammation in MS, a finding they believe could lead to a new therapeutic approach. Resources Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 